GenSpera is a leader in developing prodrug therapeutics for some of the most challenging diseases in oncology, harnessing a cutting-edge platform technology to deliver a powerful plant-derived cytotoxin directly to tumors.
GenSpera's team has deep experience in the pharmaceutical industry and drug discovery and development. Our scientific team includes leading researchers from around the globe.
Developed at Johns Hopkins University and the University of Copenhagen, GenSpera's patented technology platform that has the potential to work across a spectrum of drugs that precisely target different cancers.
Learn about GenSpera's development of mipsagargin.